^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Published date:
07/10/2020
Excerpt:
…we evaluated apoptosis via both TUNEL and apoptotic marker (c-PARP and Bax) immunoreactivity in various groups....The immunohistochemical staining results showed that the c-PARP and Bax levels were increased in the treatment groups compared with the control group, and the anlotinib combined with chemoradiation-treated group exhibited the highest levels...Furthermore, anlotinib can exert antitumor effects via its antiangiogenic activity...
DOI:
10.3389/fonc.2020.00995